본문 바로가기

다제내성/리팜핀내성결핵의 진단과 치료

Diagnosis and Treatment of Multidrug/Rifampicin-Resistant Tuberculosis

문서 유형
연구출판물 · 학술지 논문
등재
KCI
저널 순위
KCI Q3
저널
대한내과학회지 (Korean J Med)100(6) · pp.285 · 2025
피인용
KCI 0
ISSN
1738-9364

저자

  1. 김새롬제1저자부산대학교병원 호흡기내과
  2. 목정하교신저자부산대학교병원 호흡기내과

초록

To rapidly diagnose multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB), all individuals suspected of having tuberculosis should undergo the Xpert MTB/RIF assay or an equivalent test capable of simultaneously detecting Mycobacterium tuberculosis and rifampicin resistance. Upon confirmation of rifampicin resistance, treatment for MDR/RR-TB should be initiated promptly, with preference given to shorter treatment regimens, such as BPaLM, MDR-END, or BPaL. Medications included in each regimen should be administered at the recommended dosages and for the entire treatment duration. Careful monitoring and management of potential adverse effects, including bone marrow suppression, peripheral neuropathy, optic neuritis, and QT interval prolongation are essential. The advent of shorter regimens has made MDR/RR-TB treatment more convenient and accessible for many patients. However, to further improve treatment outcomes and reduce the prevalence of MDR/RR-TB in Korea, comprehensive patient-centered management should be integrated across all stages of diagnosis and treatment.

키워드

Tuberculosismultidrug-resistantRifampin다제내성결핵리팜핀결핵

식별자

KCI
ART003271166